お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
1006230

乾癬治療薬市場調査レポート:分子別(生物製剤、低分子)、投与ルート別(経口、非経口、局所)、剤形別、作用機序別-2026年までの予測-COVID-19の累積的影響

Psoriasis Therapeutics Market Research Report by Molecule, by Route of Administration, by Dosage Forms, by Mechanism of Action, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.74円
乾癬治療薬市場調査レポート:分子別(生物製剤、低分子)、投与ルート別(経口、非経口、局所)、剤形別、作用機序別-2026年までの予測-COVID-19の累積的影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の乾癬治療薬の市場規模は、2020年の164億9,057万米ドルから、2025年末までに250億8,012万米ドルに拡大すると予測されています。

COVID-19は、未曾有の世界的な公衆衛生上の緊急事態であり、あらゆる業界に影響を及ぼしてきました。この長期的影響は、予測期間中に業界の成長に影響を与えると予測されています。私たちが進めている調査では、根底にあるCOVID-19の問題と今後の道筋を確実に扱うために、調査範囲を広げています。当レポートは、消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場動向、および政府の重要な介入などを考慮しながら、COVID-19について洞察を提供しています。アップデートされた調査では、COVID-19が市場に及ぼす影響を考慮し、洞察、分析、予測などを提供しています。

当レポートでは、乾癬治療薬市場について調査し、市場の概要とともに、分子別、投与ルート別、剤形別、作用機序別、地域別の動向、COVID-19の累積的影響、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションと範囲
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画作成
    • 実行:調査実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場の見通し
  • 分子別見通し
  • 作用機序別見通し
  • 剤形別見通し
  • 投与ルート別見通し
  • 地域別見通し
  • 競合他社別見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 乾癬治療薬市場、分子別

  • 生物製剤
  • 低分子

第7章 乾癬治療薬市場、投与ルート別

  • 経口
  • 非経口
  • 局所

第8章 乾癬治療薬市場、剤形別

  • 液体
  • 半固体
  • 固体

第9章 乾癬治療薬市場、作用機序別

  • ILブロッカー
  • PDE4阻害剤
  • TNF阻害剤

第10章 南北アメリカの乾癬治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の乾癬治療薬市場

  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第12章 欧州、中東・アフリカの乾癬治療薬市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 契約、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第14章 企業のユーザビリティプロファイル

  • AbbVie Inc.
  • Amgen, Inc.
  • AstraZeneca
  • Celgene Corporation
  • Eli Lilly and Company
  • Johnson & Johnson
  • Novartis AG

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格
  • 連絡先の詳細
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2020 VS 2026 (USD BILLION)
  • FIGURE 2. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2020 (USD BILLION)
  • FIGURE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2020 (USD BILLION)
  • FIGURE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2020 (USD BILLION)
  • FIGURE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 (USD BILLION)
  • FIGURE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
  • FIGURE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET: MARKET DYNAMICS
  • FIGURE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2020 VS 2026 (%)
  • FIGURE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2020 VS 2026 (USD BILLION)
  • FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2026
  • FIGURE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2026 (USD BILLION)
  • FIGURE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2026 (USD BILLION)
  • FIGURE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (%)
  • FIGURE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (USD BILLION)
  • FIGURE 18. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2026
  • FIGURE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2026 (USD BILLION)
  • FIGURE 20. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 21. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2026 (USD BILLION)
  • FIGURE 22. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 23. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2026 (USD BILLION)
  • FIGURE 24. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 25. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2020 VS 2026 (%)
  • FIGURE 26. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2020 VS 2026 (USD BILLION)
  • FIGURE 27. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2026
  • FIGURE 28. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY LIQUID, 2018-2026 (USD BILLION)
  • FIGURE 29. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY LIQUID, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 30. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEMI-SOLID, 2018-2026 (USD BILLION)
  • FIGURE 31. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEMI-SOLID, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 32. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SOLID, 2018-2026 (USD BILLION)
  • FIGURE 33. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SOLID, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 34. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2026 (%)
  • FIGURE 35. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2026 (USD BILLION)
  • FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2026
  • FIGURE 37. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL BLOCKER, 2018-2026 (USD BILLION)
  • FIGURE 38. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL BLOCKER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 39. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, 2018-2026 (USD BILLION)
  • FIGURE 40. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 41. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2026 (USD BILLION)
  • FIGURE 42. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 43. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 44. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 45. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 46. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 47. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 48. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 49. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 50. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 51. CALIFORNIA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 52. FLORIDA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 53. ILLINOIS PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 54. NEW YORK PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 55. OHIO PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 56. PENNSYLVANIA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 57. TEXAS PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 58. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 59. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 60. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 61. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 62. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 63. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 64. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 65. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 66. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 67. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 68. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 69. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 70. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 71. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 72. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 73. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 74. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 75. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 76. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 77. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 78. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 79. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 80. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 81. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 82. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 83. GLOBAL PSORIASIS THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 84. GLOBAL PSORIASIS THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 85. GLOBAL PSORIASIS THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 86. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PSORIASIS THERAPEUTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY LIQUID, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEMI-SOLID, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SOLID, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL BLOCKER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 18. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 19. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 20. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 21. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 22. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 23. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 24. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 25. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 26. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 27. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 28. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 29. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 30. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 31. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 32. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 33. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 34. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 35. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 36. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 37. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 38. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 39. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 40. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 41. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 42. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 43. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 44. CALIFORNIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 45. CALIFORNIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 46. CALIFORNIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 47. CALIFORNIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 48. FLORIDA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 49. FLORIDA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 50. FLORIDA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 51. FLORIDA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 52. ILLINOIS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 53. ILLINOIS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 54. ILLINOIS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 55. ILLINOIS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 56. NEW YORK PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 57. NEW YORK PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 58. NEW YORK PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 59. NEW YORK PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 60. OHIO PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 61. OHIO PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 62. OHIO PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 63. OHIO PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 64. PENNSYLVANIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 65. PENNSYLVANIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 66. PENNSYLVANIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 67. PENNSYLVANIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 68. TEXAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 69. TEXAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 70. TEXAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 71. TEXAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 72. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 73. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 74. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 75. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 76. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 77. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 78. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 79. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 80. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 81. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 82. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 83. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 84. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 85. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 86. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 87. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 88. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 89. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 90. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 91. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 92. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 93. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 94. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 95. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 96. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 97. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 98. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 99. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 100. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 101. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 102. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 103. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 104. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 105. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 106. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 107. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 108. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 114. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 115. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 116. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 117. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 118. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 119. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 120. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 121. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 122. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 123. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 124. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 125. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 126. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 127. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 128. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 129. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 130. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 131. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 132. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 133. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 134. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 135. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 136. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 137. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 138. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 139. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 140. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 141. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 142. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 143. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 144. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 145. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 146. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 147. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 148. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 149. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 150. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 151. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 152. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 153. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 154. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 155. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 156. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 157. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 158. GLOBAL PSORIASIS THERAPEUTICS MARKET: SCORES
  • TABLE 159. GLOBAL PSORIASIS THERAPEUTICS MARKET: BUSINESS STRATEGY
  • TABLE 160. GLOBAL PSORIASIS THERAPEUTICS MARKET: PRODUCT SATISFACTION
  • TABLE 161. GLOBAL PSORIASIS THERAPEUTICS MARKET: RANKING
  • TABLE 162. GLOBAL PSORIASIS THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 163. GLOBAL PSORIASIS THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 164. GLOBAL PSORIASIS THERAPEUTICS MARKET: MERGER & ACQUISITION
  • TABLE 165. GLOBAL PSORIASIS THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 166. GLOBAL PSORIASIS THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 167. GLOBAL PSORIASIS THERAPEUTICS MARKET: INVESTMENT & FUNDING
  • TABLE 168. GLOBAL PSORIASIS THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 169. GLOBAL PSORIASIS THERAPEUTICS MARKET: LICENSE & PRICING
  • TABLE 170. GLOBAL PSORIASIS THERAPEUTICS MARKET: CONTACT DETAILS
目次
Product Code: MRR-035AB9C0DA47

The Global Psoriasis Therapeutics Market size was estimated at USD 16.49 Billion in 2020 and expected to reach USD 18.01 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 9.58% to reach USD 28.56 Billion by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Psoriasis Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Molecule, the Psoriasis Therapeutics Market was studied across Biologics and Small Molecules.

Based on Route of Administration, the Psoriasis Therapeutics Market was studied across Oral, Parenteral, and Topical.

Based on Dosage Forms, the Psoriasis Therapeutics Market was studied across Liquid, Semi-solid, and Solid.

Based on Mechanism of Action, the Psoriasis Therapeutics Market was studied across IL blocker, PDE4 Inhibitors, and TNF Inhibitors.

Based on Geography, the Psoriasis Therapeutics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Psoriasis Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Psoriasis Therapeutics Market, including AbbVie Inc., Amgen, Inc., Astellas Pharma Inc., AstraZeneca plc, Bausch Health Companies Inc., Biocon Limited, Boehringer Ingelheim International GmbH, Celgene Corporation, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, G & W Laboratories, GlaxoSmithKline plc, Johnson & Johnson services, inc, LEO Pharma A/S, mc2 therapeutics, Merck & Co., Inc., Novartis AG, Pfizer Inc, Sun Pharmaceutical Industries Limited, Temisis Therapeutics, and UCB S.A..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Psoriasis Therapeutics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Psoriasis Therapeutics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Psoriasis Therapeutics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Psoriasis Therapeutics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Psoriasis Therapeutics Market?
  • 6. What is the market share of the leading vendors in the Global Psoriasis Therapeutics Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Psoriasis Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Molecule Outlook
  • 3.4. Mechanism of Action Outlook
  • 3.5. Dosage Forms Outlook
  • 3.6. Route of Administration Outlook
  • 3.7. Geography Outlook
  • 3.8. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing elderly population worldwide
      • 5.1.1.2. Increasing incidence of plaque psoriasis and psoriasis arthritis
      • 5.1.1.3. Favorable reimbursement policies for such therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising prescription volume and approvals of biologic products
      • 5.1.3.2. Emerging development of new biologics and novel pipeline drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Probable health risks due to the medication
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Psoriasis Therapeutics Market, by Molecule

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Small Molecules

7. Psoriasis Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral
  • 7.4. Topical

8. Psoriasis Therapeutics Market, by Dosage Forms

  • 8.1. Introduction
  • 8.2. Liquid
  • 8.3. Semi-solid
  • 8.4. Solid

9. Psoriasis Therapeutics Market, by Mechanism of Action

  • 9.1. Introduction
  • 9.2. IL blocker
  • 9.3. PDE4 Inhibitors
  • 9.4. TNF Inhibitors

10. Americas Psoriasis Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States
    • 10.6.1. California
    • 10.6.2. Florida
    • 10.6.3. Illinois
    • 10.6.4. New York
    • 10.6.5. Ohio
    • 10.6.6. Pennsylvania
    • 10.6.7. Texas

11. Asia-Pacific Psoriasis Therapeutics Market

  • 11.1. Introduction
  • 11.2. China
  • 11.3. India
  • 11.4. Indonesia
  • 11.5. Japan
  • 11.6. Malaysia
  • 11.7. Philippines
  • 11.8. South Korea
  • 11.9. Thailand

12. Europe, Middle East & Africa Psoriasis Therapeutics Market

  • 12.1. Introduction
  • 12.2. France
  • 12.3. Germany
  • 12.4. Italy
  • 12.5. Netherlands
  • 12.6. Qatar
  • 12.7. Russia
  • 12.8. Saudi Arabia
  • 12.9. South Africa
  • 12.10. Spain
  • 12.11. United Arab Emirates
  • 12.12. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
    • 13.1.1. Quadrants
    • 13.1.2. Business Strategy
    • 13.1.3. Product Satisfaction
  • 13.2. Market Ranking Analysis
  • 13.3. Market Share Analysis, By Quadrant
  • 13.4. Market Share Analysis, By Company
  • 13.5. Competitive Scenario
    • 13.5.1. Merger & Acquisition
    • 13.5.2. Agreement, Collaboration, & Partnership
    • 13.5.3. New Product Launch & Enhancement
    • 13.5.4. Investment & Funding
    • 13.5.5. Award, Recognition, & Expansion

14. Company Usability Profiles

  • 14.1. AbbVie Inc.
  • 14.2. Amgen, Inc.
  • 14.3. Astellas Pharma Inc.
  • 14.4. AstraZeneca plc
  • 14.5. Bausch Health Companies Inc.
  • 14.6. Biocon Limited
  • 14.7. Boehringer Ingelheim International GmbH
  • 14.8. Celgene Corporation
  • 14.9. Celgene Corporation
  • 14.10. Eli Lilly and Company
  • 14.11. F. Hoffmann-La Roche AG
  • 14.12. G & W Laboratories
  • 14.13. GlaxoSmithKline plc
  • 14.14. Johnson & Johnson services, inc
  • 14.15. LEO Pharma A/S
  • 14.16. mc2 therapeutics
  • 14.17. Merck & Co., Inc.
  • 14.18. Novartis AG
  • 14.19. Pfizer Inc
  • 14.20. Sun Pharmaceutical Industries Limited
  • 14.21. Temisis Therapeutics
  • 14.22. UCB S.A.

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing
  • 15.3. Contact Details
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.